Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $13.61 and traded as high as $19.00. Assembly Biosciences shares last traded at $18.96, with a volume of 17,344 shares trading hands.
Wall Street Analysts Forecast Growth
ASMB has been the subject of a number of recent research reports. HC Wainwright restated a "neutral" rating on shares of Assembly Biosciences in a research note on Monday, March 24th. Wall Street Zen lowered shares of Assembly Biosciences from a "buy" rating to a "hold" rating in a research note on Monday, March 24th. Finally, Guggenheim initiated coverage on shares of Assembly Biosciences in a research note on Tuesday, March 25th. They set a "buy" rating and a $31.00 price target for the company.
Read Our Latest Research Report on Assembly Biosciences
Assembly Biosciences Stock Performance
The firm has a market cap of $142.68 million, a P/E ratio of -3.00 and a beta of 0.62. The stock's 50 day simple moving average is $16.27 and its 200 day simple moving average is $13.64.
Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.01) by $0.84. Assembly Biosciences had a negative net margin of 124.15% and a negative return on equity of 131.77%. The firm had revenue of $9.42 million during the quarter, compared to analyst estimates of $7.41 million. As a group, analysts forecast that Assembly Biosciences, Inc. will post -6.87 EPS for the current fiscal year.
Institutional Trading of Assembly Biosciences
Several institutional investors have recently made changes to their positions in ASMB. Gilead Sciences Inc. bought a new stake in shares of Assembly Biosciences in the 4th quarter worth $34,865,000. B Group Inc. bought a new stake in shares of Assembly Biosciences in the 4th quarter worth $799,000. Renaissance Technologies LLC boosted its holdings in shares of Assembly Biosciences by 44.3% in the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company's stock worth $1,495,000 after buying an additional 29,087 shares during the last quarter. Man Group plc purchased a new position in shares of Assembly Biosciences in the 4th quarter worth about $309,000. Finally, American Century Companies Inc. purchased a new position in shares of Assembly Biosciences in the 1st quarter worth about $113,000. Institutional investors own 19.92% of the company's stock.
Assembly Biosciences Company Profile
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Read More
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
